Edgewise Therapeutics Inc. (EWTX)
NASDAQ: EWTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 11:11 AM ET
EWTX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $4.15B
- EPS (TTM)
- -$1.86
- Dividend yield
- None
- 52-week range
- 14.25 – 48.51
- Day range
- 37.97 – 38.93
- Volume / Avg
- 247.62K / 1.35M
- Beta
- —
- Shares outstanding
- 108.60M
- Next earnings
- Nov 5, 2026
52-week range
EWTX stock today
Shares of Edgewise Therapeutics (EWTX) are trading lower on Oct 8 at $38.18, a drop of 3.51% or $1.39 per share, versus the S&P 500's 0.36% decline. At this level, EWTX sits in the middle of its 52-week range of $14.25 to $48.51: 21.3% below the high, set on Sep 17, 2026 and 167.9% above the low. EWTX is up 59.5% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 161.4%.
Edgewise Therapeutics has posted a net loss over the last twelve months (EPS of -$1.86), so its P/E ratio is not meaningful. Edgewise Therapeutics's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Edgewise Therapeutics
Company profileEdgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Kevin Koch Ph.D.
- Headquarters
- Boulder, CO
- Employees
- 127
- IPO year
- 2021
- Website
- edgewisetx.com
Financial highlights
Full financialsEdgewise Therapeutics reported a net loss of $167.8 million, compared with a loss of $133.8 million a year earlier. Diluted earnings per share came in at -$1.63.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-167.79M | $-133.81M | $-100.16M | $-67.64M | $-42.81M |
| EPS (diluted) | $-1.63 | $-1.45 | $-1.57 | $-1.26 | $-1.14 |
Analyst forecast
ForecastConsensus (13 analysts)
buy
Avg. price target
$52.62+37.82%
- Strong buy 3
- Buy 8
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $-0.55
- Last reported (Q2 2026)
- Aug 6, 2026
- EPS actual vs est.
- $-0.53 vs —
EWTX news
All EWTX newsEdgewise Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| INDVIndivior Pharmaceuticals Inc. | 35.51 | -1.73% | $4.19B | vs EWTX |
| DNTHDianthus Therapeutics Inc. | 82.44 | -2.88% | $4.61B | vs EWTX |
| ABCLAbCellera Biologics Inc. | 12.20 | -4.95% | $3.95B | vs EWTX |
| TVTXTravere Therapeutics Inc. | 51.69 | -3.27% | $4.87B | vs EWTX |
| ERASErasca Inc. | 14.18 | +0.42% | $4.96B | vs EWTX |
| TLXTelix Pharmaceuticals Limited ADR | 10.95 | -1.53% | $3.72B | vs EWTX |
| GRFSGrifols S.A. ADR | 7.32 | -2.47% | $4.98B | vs EWTX |
| OGNOrganon & Co. | 13.79 | 0.00% | $3.62B | vs EWTX |
Indexes, lists and sector
Edgewise Therapeutics stock FAQ
What is Edgewise Therapeutics's stock price today?
EWTX last traded at $38.18 as of Oct 8, 11:11 AM EDT, down 3.51% on the day. Prices are delayed at least 15 minutes.
When is Edgewise Therapeutics's next earnings date?
Edgewise Therapeutics is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $-0.55.
Who is Edgewise Therapeutics's CEO?
Dr. Kevin Koch Ph.D. is the chief executive officer of Edgewise Therapeutics Inc., which has about 127 employees.
What is the EWTX 52-week high?
The 52-week high for EWTX is $48.51 and the 52-week low is $14.25. The stock is currently 21.3% below its high.